NCT02924376 · OUTCOME

First-order Absorption Rate Constant (ka) of Pemigatinib

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) · Source last updated 2025-08-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: 1/hour
Interval / dispersion: Standard Deviation
Time frame: Predose; 1-2 hours post-dose; 4-12 hours post-dose

What was measured

First-order absorption rate constant is defined as the rate at which a drug enters into the system.

Analysis population: Pharmacokinetic (PK) Population: all participants contributing at least one sample for PK analysis

Groups in this outcome

All Cohorts

Participants with FGFR2 rearrangements or fusions (Cohort A), participants with all other FGF/FGFR alterations (Cohort B), participants with no FGF/FGFR alterations (Cohort C; United States only), and participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally (Other) self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Cohorts	136

Reported measurements

Source class 1

Values in 1/hour · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
All Cohorts	1.29	0.827	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
0.827
value
1.29

denoms

counts
group Id
OG000
value
136
units
Participants

description

First-order absorption rate constant is defined as the rate at which a drug enters into the system.

dispersion Type

Standard Deviation

groups

description
Participants with FGFR2 rearrangements or fusions (Cohort A), participants with all other FGF/FGFR alterations (Cohort B), participants with no FGF/FGFR alterations (Cohort C; United States only), and participants with an FGF/FGFR status for whom the local laboratory FGF/FGFR results could not be confirmed centrally (Other) self-administered oral pemigatinib at a starting dose of 13.5 mg QD on a 2-weeks-on therapy/1-week-off schedule in 21-day cycles. Pemigatinib was administered until documented disease progression or unacceptable toxicity.
id
OG000
title
All Cohorts

param Type

MEAN

population Description

Pharmacokinetic (PK) Population: all participants contributing at least one sample for PK analysis

reporting Status

POSTED

time Frame

Predose; 1-2 hours post-dose; 4-12 hours post-dose

title

First-order Absorption Rate Constant (ka) of Pemigatinib

type

SECONDARY

unit Of Measure

1/hour

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice